NICM
CRNX

Neo Ivy Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Neo Ivy Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.1K Buy
+1,794
New +$66.7K 0.02% 305
2025
Q3 		– Sell
-176
Closed -$5.06K – 413
2025
Q2 		$5.06K Buy
+176
New +$5.43K ﹤0.01% 333

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neo Ivy Capital Management's CRNX Position: Q2 2026 in Review

Neo Ivy Capital Management opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 1,794 shares worth $67.1K. The stake represents 0.02% of the portfolio and ranks #305 among its holdings. This is a return to the name: Neo Ivy Capital Management previously reported a position in CRNX as recently as Q2 2025.

Neo Ivy Capital Management first reported a position in CRNX in Q2 2025 and has held it in 2 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Neo Ivy Capital Management held 1,794 shares of Crinetics Pharmaceuticals worth $67.1K as of Q2 2026.
  • Crinetics Pharmaceuticals was a new Neo Ivy Capital Management position in Q2 2026.
  • Crinetics Pharmaceuticals made up 0.02% of Neo Ivy Capital Management's portfolio in Q2 2026, its #305 holding.
  • Neo Ivy Capital Management first reported a position in Crinetics Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Neo Ivy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.